CSIMarket

 

Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway


Published / Modified Aug 01 2024
CSIMarket Team / CSIMarket.com




Intelligent Bio Solutions: Pivotal FDA Study and Industry Adoption Drive Growth in Non-Invasive Testing Technology





Sources for this article: Intelligent Bio Solutions Inc Press release, News Wire, Globe Newswire, Business wire, Pr newswire.... and Supply Chain Analysis by CSIMarket.com


  More Intelligent Bio Solutions Inc 's News
Intelligent Bio Solutions Inc

Advancements in Non-Invasive Drug Screening Bio Solutions Moves Closer to FDA Approval

September 5, 2024
Intelligent Bio Solutions Inc

Bio Solutions Inc. Shows Massive Customer Employee Growth Amidst Moderate Stock Performance and Financial Challenges,

September 3, 2024
Intelligent Bio Solutions Inc

Bio Solutions Surges Ahead with 1,000 Drug Testing Readers Installed, but Market Challenges Loom

August 21, 2024


  More Partnership News
Partnership

Rezolve AIs Triumphant Trio Strategic Partnerships Set to Revolutionize Digital Commerce,

September 13, 2024
Partnership

BioNexus Gene Lab Corp. Forms Strategic Partnership Amidst Stock Struggles

September 12, 2024
Partnership

Innovation Amidst Challenge Bridgeline Partners with Human Element to Boost AI-Powered Search for eCommerce Success...

September 12, 2024





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com